News
Secretome Therapeutics to Present at the 2026 J.P. Morgan Healthcare Conference
PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that it will present at the 2026 J.P. Morgan...
Secretome Therapeutics Initiates Phase 1 Clinical Trial of STM-01 in Patients with Dilated Cardiomyopathy
PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics today announced the launch of a Phase 1, dose-escalating trial of STM-01, Secretome’s neonatal cardiac progenitor cell (nCPC) product, for the treatment of heart failure in young adults with dilated cardiomyopathy...
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01
FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 /PRNewswire/ -- RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and...
Secretome Therapeutics Awarded $400,000 Grant from Friedreich’s Ataxia Research Alliance (FARA)
Funding will support preclinical evaluation of STM-01 and STM-03 for Friedreich’s Ataxia. Secretome Therapeutics announced today that it has been awarded a $400,000 research grant from the Friedreich’s Ataxia Research Alliance (FARA), a leading global patient advocacy...
Secretome Therapeutics Appoints Dr. Marshelle Smith Warren as Chief Medical Officer
DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the appointment of Marshelle Smith Warren, MD, as Chief Medical Officer. Dr. Warren is...
Secretome Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1 Study of STM-01 in Heart Failure with Preserved Ejection Fraction
PLANO, Texas & BALTIMORE--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced dosing of the first patient in its Phase 1 clinical trial...
Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the company’s neonatal cardiac progenitor cell...
Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
THE WOODLANDS, Texas and DALLAS, Jan. 22, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies...
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing. This funding will enable Secretome to...
Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21
Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the allowance of a composition of matter patent for its lead asset, STM-01, a novel nCPC product. Recently, a composition of matter patent was also issued for STM-21, the company’s lead secretome product derived from nCPC.